Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 12 December 2017

Indication(s)




Medicinal product no longer authorised



This medicinal product is for diagnostic use only.
 
Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualization and helps with the characterization of focal lesions and abnormal structures in the CNS and liver in adult patients and in children of two years and older with known or highly suspected pathology.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Pain, Agitation and Delirium (PAD) Management

Pain, Agitation and Delirium (PAD) Management

Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.

+ 4 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000745
Orphan designation No
Date First Approved 23-07-2007
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Mallinckrodt Deutschland GmbH
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions